CD274 and neoplasm: Therefore, VEGF/VEGFR monoclonal antibodies or tyrosine kinase inhibitors make tumor cells more sensitive to PD-L1 inhibitors, combining them with PD-L1 inhibitors enhances the sensitivity and effectiveness of anti-angiogenic therapy [386].